Ocular manifestations following COVID-19 vaccination.

Padmamalini Mahendradas, Sai Bhakti Mishra, Rohini Sangoram, Sanjay Srinivasan, Ankush Kawali, Aditya Patil, Rohit Shetty
{"title":"Ocular manifestations following COVID-19 vaccination.","authors":"Padmamalini Mahendradas, Sai Bhakti Mishra, Rohini Sangoram, Sanjay Srinivasan, Ankush Kawali, Aditya Patil, Rohit Shetty","doi":"10.1186/s12348-023-00358-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunologic and inflammatory adverse effects following vaccination against COVID-19 are being reported. While some reactions may develop denovo others concern its immunogenic effect in patients with pre-existing inflammatory conditions.</p><p><strong>Methods: </strong>Retrospective consecutive patients diagnosed with ocular inflammatory manifestations within 8 weeks of receiving COVID-19 vaccination who presented to a tertiary eye care centre in South India.</p><p><strong>Results: </strong>Ninety-eight eyes of 67 patients presenting with ocular inflammatory manifestations within 8 weeks following COVID-19 vaccination were studied. The mean age was 43 years (+/- 14.82; range 19-80 years). The most common presentations were anterior uveitis (n = 31, 31.7%), followed by panuveitis (n = 24, 24.5%). The mean time to onset of symptoms was 25 days (+/- 15.48; range 2-55 days) following a dose of vaccine. Among all patients, 39 (58.2%) had a previous history of ocular inflammation. Mean presenting visual acuity was 0.4 (0-4) logMAR units and mean final visual acuity was 0.2 (0-4) logMAR units. The causes for reduced vision included of cystoid macular edema (n=2, 2%), chorioretinal atrophy (n=2.2%), optic atrophy (n=1.1%), retinal vascular occlusion (n=1.1%) and acute retinal necrosis (n=1.1%).</p><p><strong>Conclusion: </strong>Infective and immunogenic adverse events should be watched out for after COVID-19 vaccination. It is difficult to establish causality for such manifestations, nevertheless, most of them were mild and had good final visual outcomes.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516807/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-023-00358-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Immunologic and inflammatory adverse effects following vaccination against COVID-19 are being reported. While some reactions may develop denovo others concern its immunogenic effect in patients with pre-existing inflammatory conditions.

Methods: Retrospective consecutive patients diagnosed with ocular inflammatory manifestations within 8 weeks of receiving COVID-19 vaccination who presented to a tertiary eye care centre in South India.

Results: Ninety-eight eyes of 67 patients presenting with ocular inflammatory manifestations within 8 weeks following COVID-19 vaccination were studied. The mean age was 43 years (+/- 14.82; range 19-80 years). The most common presentations were anterior uveitis (n = 31, 31.7%), followed by panuveitis (n = 24, 24.5%). The mean time to onset of symptoms was 25 days (+/- 15.48; range 2-55 days) following a dose of vaccine. Among all patients, 39 (58.2%) had a previous history of ocular inflammation. Mean presenting visual acuity was 0.4 (0-4) logMAR units and mean final visual acuity was 0.2 (0-4) logMAR units. The causes for reduced vision included of cystoid macular edema (n=2, 2%), chorioretinal atrophy (n=2.2%), optic atrophy (n=1.1%), retinal vascular occlusion (n=1.1%) and acute retinal necrosis (n=1.1%).

Conclusion: Infective and immunogenic adverse events should be watched out for after COVID-19 vaccination. It is difficult to establish causality for such manifestations, nevertheless, most of them were mild and had good final visual outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎疫苗接种后的眼部表现。
背景:报道了接种新冠肺炎疫苗后的免疫和炎症不良反应。虽然一些反应可能会发展为denovo,但其他反应则涉及其对已有炎症条件的患者的免疫原性影响。方法:回顾性研究在接受新冠肺炎疫苗接种后8周内被诊断为眼部炎症表现的连续患者,这些患者在南印度的三级眼科护理中心就诊。平均年龄43岁(+/-14.82;范围19-80岁)。最常见的表现是前葡萄膜炎(n = 31.7%),其次为全葡萄膜炎(n = 24,24.5%)。接种一剂疫苗后症状出现的平均时间为25天(+/-15.48;范围为2-55天)。在所有患者中,39人(58.2%)有眼部炎症病史。平均呈现视力为0.4(0-4)logMAR单位,平均最终视力为0.2(0-4(logMAR)单位。视力下降的原因包括囊样黄斑水肿(n=2,2%)、脉络膜视网膜萎缩(n=2.2%)、视神经萎缩(n=1.1%)、视网膜血管阻塞(n=1.1%,1.1%)和急性视网膜坏死(n=1.1%)。结论:接种新冠肺炎疫苗后应注意感染性和免疫原性不良事件。很难确定这种表现的因果关系,然而,大多数表现都很轻微,最终视觉效果良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.80
自引率
3.40%
发文量
39
审稿时长
13 weeks
期刊最新文献
Ocular loaiasis in France: the first case report from Brittany. Effect of intravitreal injection of anti-interleukin (IL)-6 antibody in experimental autoimmune uveitis in mice. Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases. Safety and efficacy of intravitreal dexamethasone implantation along with phacoemulsification and intraocular lens implantation in children with uveitis. Foscarnet eyedrops for the treatment of refractory herpetic keratitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1